Evidence record · ER-GLP1-IMPURITIES-033
GLP-1 impurities: what a laboratory study can tell us
Claim assessed: This laboratory paper establishes the safety or equivalence of a separate GLP-1 vial.
GLP-1 product impurities are unwanted substances in a drug sample. Kopp and colleagues’ 2026 lab study found differences in selected follow-on and compounded semaglutide and liraglutide products: copies of existing medicines and pharmacy-prepared products. It did not measure harm in patients and cannot establish what is in a different vial. Kopp et al., 2026
These fields assess the claim stated above. They do not score the quality of an individual laboratory measurement or confirm a seller’s product.
What did the researchers examine?
The team used chemical tests, tests of how products change over time, and a test of how cells show peptide fragments to the immune system. They found differences in impurities and some stability results. These tests explore a possible immune response. They do not show how often people have one. Study methods and results
Why does the funding disclosure matter?
Novo Nordisk funded the study. Its authors held shares and worked, or had worked, for the company. Readers should weigh that interest alongside the findings. Funding and conflicts
Which questions still need separate evidence?
A test result is useful only for the question it can answer. The report should name the sample, the test and its limits. Our guide to what peptide tests can prove shows how to match these parts.
| Question | Evidence to look for |
|---|---|
| Which substance was measured? | A method suited to identifying that substance. |
| How much was present? | A suitable quantity assay, with units and calibration. |
| Which other substances were assessed? | The analytes and detection limits stated in the report. |
| Does the result apply to this vial? | A defensible link between the tested sample and the item in question. |
The name of a machine alone is not enough. Ask what the test looked for, what it could miss and how its result was judged. Our guide to methods and uncertainty explains those limits. “Not detected” does not mean a substance was proved absent at every possible level.
How does What’s in the Vial? use this evidence?
We place this paper with product-quality research. Our evidence-rating method does not use it to give a seller a global score or to rate a treatment. We ask what was tested, whether it matches the product a reader has, and which claim the result can support.
The same care is needed with a certificate of analysis, or COA: a document that reports test results. If it gives a percentage, ask what that number means. Is it the area of a peak on a chart? Is it how much drug is in the vial? Does the sample match the item in your hand? These are different claims.
For the wider picture, read grey-market versus prescribed GLP-1 products. This record is not advice to stop or switch a prescribed medicine. If you have concerns about your own medicine, speak to the person who prescribed it or to a pharmacist.
Sources and review history
Full published paper and declarations checked. Source check: 6 September 2026. Published 6 September 2026. Recheck by 6 March 2027, or earlier after a correction, new version, peer-reviewed publication or relevant regulatory change.